Disruption of the Tff1 gene in mice using CRISPR/Cas9 promotes body weight reduction and gastric tumorigenesis

被引:10
作者
Kim H. [1 ]
Jeong H. [2 ]
Cho Y. [2 ]
Lee J. [1 ]
Nam K.T. [2 ]
Lee H.-W. [1 ]
机构
[1] Department of Biochemistry, College of Life Science and Biotechnology and Yonsei Laboratory Animal Research Center, Yonsei University, Seoul
[2] Severance Biomedical Science Institute, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul
关键词
CRISPR/Cas9; gastric cancer; Tff1; Tff1-knockout mouse;
D O I
10.5625/lar.2018.34.4.257
中图分类号
学科分类号
摘要
Trefoil factor 1 (TFF1, also known as pS2) is strongly expressed in the gastrointestinal mucosa and plays a critical role in the differentiation of gastric glands. Since approximately 50% of all human gastric cancers are associated with decreased TFF1 expression, it is considered a tumor suppressor gene. Tff1 deficiency in mice results in histological changes in the antral and pyloric gastric mucosa, with severe hyperplasia and dysplasia of epithelial cells, resulting in the development of antropyloric adenoma. Here, we generated Tff1-knockout (KO) mice, without a neomycin resistant (NeoR) cassette, using the clustered regularly interspaced short palindromic repeats/CRISPR-associated nuclease 9 (CRSIPR/Cas9) system. Though our Tff1-KO mice showed phenotypes very similar to the previous embryonic stem (ES)-cell-based KO mice, they differed from the previous reports in that a reduction in body weight was observed in males. These results demonstrate that these newly established Tff1-KO mice are useful tools for investigating genetic and environmental factors influencing gastric cancer, without the effects of artificial gene insertion. Furthermore, these findings suggest a novel hypothesis that Tff1 expression influences gender differences. © 2018, The Author(s).
引用
收藏
页码:257 / 263
页数:6
相关论文
共 25 条
[1]  
Roder D.M., The epidemiology of gastric cancer, Gastric Cancer, 5, pp. 5-11, (2002)
[2]  
Kamangar F., Dores G.M., Anderson W.F., Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world, J Clin Oncol, 24, 14, pp. 2137-2150, (2006)
[3]  
Muoz N., Franceschi S., Epidemiology of gastric cancer and perspectives for prevention, Salud Publica Mex, 39, 4, pp. 318-330, (1997)
[4]  
Hohenberger P., Gretschel S., Gastric cancer, Lancet, 362, 9380, pp. 305-315, (2003)
[5]  
Shi S.Q., Cai J.T., Yang J.M., Expression of trefoil factors 1 and 2 in precancerous condition and gastric cancer, World J Gastroenterol, 12, 19, pp. 3119-3122, (2006)
[6]  
Jakowlew S.B., Breathnach R., Jeltsch J.M., Masiakowski P., Chambon P., Sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7, Nucleic Acids Res, 12, 6, pp. 2861-2878, (1984)
[7]  
Xiao P., Ling H., Lan G., Liu J., Hu H., Yang R., Trefoil factors: Gastrointestinal-specific proteins associated with gastric cancer, Clin Chim Acta, 450, (2015)
[8]  
Lefebvre O., Chenard M.P., Masson R., Linares J., Dierich A., LeMeur M., Wendling C., Tomasetto C., Chambon P., Rio M.C., Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein, Science, 274, 5285, pp. 259-262, (1996)
[9]  
Ribieras S., Tomasetto C., Rio M.C., The pS2/TFF1 trefoil factor, from basic research to clinical applications, Biochim Biophys Acta, 1378, 1, pp. 61-77, (1998)
[10]  
Rio M.C., Bellocq J.P., Daniel J.Y., Tomasetto C., Lathe R., Chenard M.P., Batzenschlager A., Chambon P., Breast cancer-associated pS2 protein: synthesis and secretion by normal stomach mucosa, Science, 241, 4866, pp. 705-708, (1988)